Open AccessThe Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence
Author(s) -
Manasvi Gupta,
Shiavax J. Rao,
Gaurav Manek,
Gregg C. Fonarow,
Raktim Ghosh
Publication year - 2021
Publication title -
therapeutics and clinical risk management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.719
H-Index - 55
eISSN - 1178-203X
pISSN - 1176-6336
DOI - 10.2147/tcrm.s275076
Subject(s) - dapagliflozin , medicine , heart failure , guideline , intensive care medicine , ejection fraction , clinical trial , diabetes mellitus , randomized controlled trial , management of heart failure , heart failure with preserved ejection fraction , cardiology , type 2 diabetes , endocrinology , pathology
The burden and cost of heart failure management, primarily in the form of hospitalization in the setting of decompensated heart failure, continue to be some of the biggest clinical challenges in cardiovascular medicine. In recently published randomized controlled trials, including DAPA-HF, sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin was shown to reduce hospitalization from heart failure or mortality associated with cardiovascular causes, when added to existing guideline-directed medical therapy. The American College of Cardiology (ACC) released a Clinical Pathway guideline that recommends the use of dapagliflozin in clinical management of heart failure, with or without diabetes. Furthermore, the results of the DAPA-CKD trial broaden the utility of dapagliflozin as a therapeutic option in patients with advanced kidney disease. In this article, the authors explore the existing evidence on dapagliflozin in heart failure with reduced ejection fraction and highlight the need for further research on uses of dapagliflozin in the world of heart failure.